Problems in interpreting diagnostic tests for HER2 may be compromising patient access to effective treatments. As new versions of therapies targeting HER2 work their way through clinical trials, will the situation get even murkier? Malorye Allison investigates.
This is a preview of subscription content, log in via an institution to check access.
References
Phillips, K.A. et al. Cancer 115, 5166–5174 (2009).
McArthur, H.L. & Hudis, C. Clin. Cancer Res. 15, 6311–6313 (2009).
Perez, E.A. et al. J. Clin. Oncol. 25, 512, Suppl. 18S (2007).
McArthur, H.L. et al., abstract 1005, presented at European CanCer Organization 15 and 34th European Society for Medical Oncology Multidisciplinary Congress, Berlin, Sept. 20–24, 2009.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Allison, M. The HER2 testing conundrum. Nat Biotechnol 28, 117–119 (2010). https://doi.org/10.1038/nbt0210-117
Issue Date:
DOI: https://doi.org/10.1038/nbt0210-117
- Springer Nature America, Inc.
This article is cited by
-
Using in vivo fluorescence lifetime imaging to detect HER2-positive tumors
EJNMMI Research (2018)
-
Ultrasmall targeted nanoparticles with engineered antibody fragments for imaging detection of HER2-overexpressing breast cancer
Nature Communications (2018)
-
Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines
Scientific Reports (2017)
-
Opening the Regulatory Black Box of Clinical Cancer Research: Transnational Expertise Networks and “Disruptive” Technologies
Minerva (2017)
-
Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH
Gastric Cancer (2016)